nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2A6—Progesterone—uterine cancer	0.0848	0.126	CbGbCtD
Cyclophosphamide—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0631	0.0936	CbGbCtD
Cyclophosphamide—CYP3A7—Progesterone—uterine cancer	0.058	0.0859	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.058	0.0859	CbGbCtD
Cyclophosphamide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.044	0.0653	CbGbCtD
Cyclophosphamide—CYP3A5—Progesterone—uterine cancer	0.0435	0.0645	CbGbCtD
Cyclophosphamide—CYP2C8—Progesterone—uterine cancer	0.0418	0.062	CbGbCtD
Cyclophosphamide—CYP2C19—Progesterone—uterine cancer	0.0351	0.052	CbGbCtD
Cyclophosphamide—CYP2C9—Progesterone—uterine cancer	0.0292	0.0432	CbGbCtD
Cyclophosphamide—ABCB1—Progesterone—uterine cancer	0.0283	0.042	CbGbCtD
Cyclophosphamide—CYP2D6—Progesterone—uterine cancer	0.0267	0.0395	CbGbCtD
Cyclophosphamide—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0256	0.0379	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—uterine cancer	0.0224	0.0333	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—uterine cancer	0.0195	0.0288	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—uterine cancer	0.0187	0.0277	CbGbCtD
Cyclophosphamide—CYP3A4—Progesterone—uterine cancer	0.017	0.0251	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—uterine cancer	0.0168	0.025	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—uterine cancer	0.0127	0.0188	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—uterine cancer	0.00864	0.0128	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—uterine cancer	0.00814	0.0121	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—uterine cancer	0.00759	0.0112	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—uterine cancer	0.00518	0.00767	CbGbCtD
Cyclophosphamide—Mouth ulceration—Doxorubicin—uterine cancer	0.000136	0.000442	CcSEcCtD
Cyclophosphamide—Bladder pain—Doxorubicin—uterine cancer	0.000136	0.000442	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Epirubicin—uterine cancer	0.000136	0.000441	CcSEcCtD
Cyclophosphamide—Flushing—Etoposide—uterine cancer	0.000135	0.000439	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000135	0.000439	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Epirubicin—uterine cancer	0.000135	0.000439	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Doxorubicin—uterine cancer	0.000134	0.000435	CcSEcCtD
Cyclophosphamide—Dizziness—Progesterone—uterine cancer	0.000134	0.000435	CcSEcCtD
Cyclophosphamide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000131	0.000427	CcSEcCtD
Cyclophosphamide—Hepatic failure—Epirubicin—uterine cancer	0.000131	0.000427	CcSEcCtD
Cyclophosphamide—Chills—Etoposide—uterine cancer	0.000131	0.000425	CcSEcCtD
Cyclophosphamide—Sepsis—Doxorubicin—uterine cancer	0.000131	0.000424	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00013	0.000423	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Epirubicin—uterine cancer	0.00013	0.000423	CcSEcCtD
Cyclophosphamide—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00013	0.000421	CcSEcCtD
Cyclophosphamide—Alopecia—Etoposide—uterine cancer	0.000129	0.000418	CcSEcCtD
Cyclophosphamide—Vomiting—Progesterone—uterine cancer	0.000129	0.000418	CcSEcCtD
Cyclophosphamide—Renal failure acute—Epirubicin—uterine cancer	0.000128	0.000415	CcSEcCtD
Cyclophosphamide—Rash—Progesterone—uterine cancer	0.000128	0.000414	CcSEcCtD
Cyclophosphamide—Dermatitis—Progesterone—uterine cancer	0.000127	0.000414	CcSEcCtD
Cyclophosphamide—Phlebitis—Doxorubicin—uterine cancer	0.000127	0.000412	CcSEcCtD
Cyclophosphamide—Headache—Progesterone—uterine cancer	0.000127	0.000412	CcSEcCtD
Cyclophosphamide—Hot flush—Epirubicin—uterine cancer	0.000126	0.00041	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Doxorubicin—uterine cancer	0.000126	0.000408	CcSEcCtD
Cyclophosphamide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000125	0.000407	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Epirubicin—uterine cancer	0.000125	0.000406	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000125	0.000406	CcSEcCtD
Cyclophosphamide—Decreased appetite—Dactinomycin—uterine cancer	0.000124	0.000404	CcSEcCtD
Cyclophosphamide—Dysgeusia—Etoposide—uterine cancer	0.000124	0.000403	CcSEcCtD
Cyclophosphamide—Renal impairment—Epirubicin—uterine cancer	0.000124	0.000403	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Epirubicin—uterine cancer	0.000123	0.000401	CcSEcCtD
Cyclophosphamide—Fatigue—Dactinomycin—uterine cancer	0.000123	0.0004	CcSEcCtD
Cyclophosphamide—Pain—Dactinomycin—uterine cancer	0.000122	0.000397	CcSEcCtD
Cyclophosphamide—Muscle spasms—Etoposide—uterine cancer	0.000122	0.000396	CcSEcCtD
Cyclophosphamide—Hepatic failure—Doxorubicin—uterine cancer	0.000121	0.000395	CcSEcCtD
Cyclophosphamide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000121	0.000394	CcSEcCtD
Cyclophosphamide—Cardiac failure—Epirubicin—uterine cancer	0.000121	0.000393	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Doxorubicin—uterine cancer	0.00012	0.000391	CcSEcCtD
Cyclophosphamide—Nausea—Progesterone—uterine cancer	0.00012	0.00039	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Epirubicin—uterine cancer	0.000118	0.000385	CcSEcCtD
Cyclophosphamide—Renal failure acute—Doxorubicin—uterine cancer	0.000118	0.000384	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000118	0.000383	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Dactinomycin—uterine cancer	0.000118	0.000383	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Etoposide—uterine cancer	0.000118	0.000382	CcSEcCtD
Cyclophosphamide—Anaemia—Etoposide—uterine cancer	0.000117	0.000381	CcSEcCtD
Cyclophosphamide—Hot flush—Doxorubicin—uterine cancer	0.000117	0.000379	CcSEcCtD
Cyclophosphamide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000117	0.000379	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Doxorubicin—uterine cancer	0.000116	0.000376	CcSEcCtD
Cyclophosphamide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000116	0.000375	CcSEcCtD
Cyclophosphamide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000115	0.000375	CcSEcCtD
Cyclophosphamide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000115	0.000373	CcSEcCtD
Cyclophosphamide—Renal impairment—Doxorubicin—uterine cancer	0.000115	0.000373	CcSEcCtD
Cyclophosphamide—Malaise—Etoposide—uterine cancer	0.000114	0.000371	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—uterine cancer	0.000114	0.000371	CcSEcCtD
Cyclophosphamide—Leukopenia—Etoposide—uterine cancer	0.000113	0.000369	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dactinomycin—uterine cancer	0.000113	0.000367	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Epirubicin—uterine cancer	0.000112	0.000365	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—uterine cancer	0.000112	0.000364	CcSEcCtD
Cyclophosphamide—Cough—Etoposide—uterine cancer	0.000111	0.000359	CcSEcCtD
Cyclophosphamide—Convulsion—Etoposide—uterine cancer	0.00011	0.000357	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—uterine cancer	0.00011	0.000356	CcSEcCtD
Cyclophosphamide—Hypertension—Etoposide—uterine cancer	0.000109	0.000356	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000109	0.000355	CcSEcCtD
Cyclophosphamide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000109	0.000354	CcSEcCtD
Cyclophosphamide—Chest pain—Etoposide—uterine cancer	0.000108	0.000351	CcSEcCtD
Cyclophosphamide—Discomfort—Etoposide—uterine cancer	0.000107	0.000347	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000106	0.000345	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—uterine cancer	0.000106	0.000343	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Dactinomycin—uterine cancer	0.000105	0.000342	CcSEcCtD
Cyclophosphamide—Confusional state—Etoposide—uterine cancer	0.000104	0.000339	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—uterine cancer	0.000104	0.000337	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Etoposide—uterine cancer	0.000103	0.000336	CcSEcCtD
Cyclophosphamide—Infection—Etoposide—uterine cancer	0.000103	0.000334	CcSEcCtD
Cyclophosphamide—Asthenia—Dactinomycin—uterine cancer	0.000103	0.000333	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Etoposide—uterine cancer	0.000101	0.000329	CcSEcCtD
Cyclophosphamide—Tachycardia—Etoposide—uterine cancer	0.000101	0.000328	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Etoposide—uterine cancer	0.0001	0.000325	CcSEcCtD
Cyclophosphamide—Anorexia—Etoposide—uterine cancer	9.86e-05	0.00032	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	9.83e-05	0.000319	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—uterine cancer	9.78e-05	0.000318	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—uterine cancer	9.76e-05	0.000317	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—uterine cancer	9.69e-05	0.000315	CcSEcCtD
Cyclophosphamide—Hypotension—Etoposide—uterine cancer	9.67e-05	0.000314	CcSEcCtD
Cyclophosphamide—Paraesthesia—Etoposide—uterine cancer	9.29e-05	0.000302	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—uterine cancer	9.28e-05	0.000302	CcSEcCtD
Cyclophosphamide—Dyspnoea—Etoposide—uterine cancer	9.22e-05	0.0003	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—uterine cancer	9.2e-05	0.000299	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—uterine cancer	9.15e-05	0.000297	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—uterine cancer	9.09e-05	0.000295	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	9.02e-05	0.000293	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—uterine cancer	9.01e-05	0.000293	CcSEcCtD
Cyclophosphamide—Decreased appetite—Etoposide—uterine cancer	8.99e-05	0.000292	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—uterine cancer	8.96e-05	0.000291	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—uterine cancer	8.94e-05	0.00029	CcSEcCtD
Cyclophosphamide—Fatigue—Etoposide—uterine cancer	8.92e-05	0.00029	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—uterine cancer	8.91e-05	0.00029	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—uterine cancer	8.86e-05	0.000288	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—uterine cancer	8.86e-05	0.000288	CcSEcCtD
Cyclophosphamide—Pain—Etoposide—uterine cancer	8.85e-05	0.000288	CcSEcCtD
Cyclophosphamide—Constipation—Etoposide—uterine cancer	8.85e-05	0.000288	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—uterine cancer	8.84e-05	0.000287	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—uterine cancer	8.72e-05	0.000283	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—uterine cancer	8.67e-05	0.000282	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—uterine cancer	8.59e-05	0.000279	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Etoposide—uterine cancer	8.53e-05	0.000277	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—uterine cancer	8.51e-05	0.000277	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—uterine cancer	8.49e-05	0.000276	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—uterine cancer	8.49e-05	0.000276	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—uterine cancer	8.46e-05	0.000275	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	8.34e-05	0.000271	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—uterine cancer	8.31e-05	0.00027	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—uterine cancer	8.27e-05	0.000269	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—uterine cancer	8.25e-05	0.000268	CcSEcCtD
Cyclophosphamide—Urticaria—Etoposide—uterine cancer	8.22e-05	0.000267	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—uterine cancer	8.2e-05	0.000267	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—uterine cancer	8.2e-05	0.000267	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—uterine cancer	8.2e-05	0.000267	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—uterine cancer	8.18e-05	0.000266	CcSEcCtD
Cyclophosphamide—Body temperature increased—Etoposide—uterine cancer	8.18e-05	0.000266	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—uterine cancer	8.18e-05	0.000266	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—uterine cancer	8.16e-05	0.000265	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—uterine cancer	8.16e-05	0.000265	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—uterine cancer	8.12e-05	0.000264	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—uterine cancer	8.07e-05	0.000262	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—uterine cancer	8.02e-05	0.000261	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—uterine cancer	7.87e-05	0.000256	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—uterine cancer	7.85e-05	0.000255	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—uterine cancer	7.72e-05	0.000251	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—uterine cancer	7.69e-05	0.00025	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—uterine cancer	7.62e-05	0.000248	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—uterine cancer	7.61e-05	0.000247	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—uterine cancer	7.59e-05	0.000247	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—uterine cancer	7.58e-05	0.000246	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—uterine cancer	7.57e-05	0.000246	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—uterine cancer	7.55e-05	0.000245	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—uterine cancer	7.55e-05	0.000245	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—uterine cancer	7.52e-05	0.000244	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—uterine cancer	7.42e-05	0.000241	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—uterine cancer	7.32e-05	0.000238	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—uterine cancer	7.32e-05	0.000238	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—uterine cancer	7.29e-05	0.000237	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—uterine cancer	7.28e-05	0.000237	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—uterine cancer	7.21e-05	0.000234	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—uterine cancer	7.14e-05	0.000232	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—uterine cancer	7.11e-05	0.000231	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—uterine cancer	7.08e-05	0.00023	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—uterine cancer	7.04e-05	0.000229	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—uterine cancer	7.01e-05	0.000228	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—uterine cancer	6.96e-05	0.000226	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—uterine cancer	6.84e-05	0.000222	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—uterine cancer	6.83e-05	0.000222	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—uterine cancer	6.78e-05	0.00022	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—uterine cancer	6.75e-05	0.000219	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—uterine cancer	6.7e-05	0.000218	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—uterine cancer	6.67e-05	0.000217	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—uterine cancer	6.59e-05	0.000214	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—uterine cancer	6.58e-05	0.000214	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—uterine cancer	6.58e-05	0.000214	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—uterine cancer	6.57e-05	0.000213	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—uterine cancer	6.53e-05	0.000212	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—uterine cancer	6.52e-05	0.000212	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—uterine cancer	6.52e-05	0.000212	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—uterine cancer	6.48e-05	0.000211	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—uterine cancer	6.44e-05	0.000209	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—uterine cancer	6.41e-05	0.000208	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—uterine cancer	6.36e-05	0.000207	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—uterine cancer	6.32e-05	0.000205	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—uterine cancer	6.28e-05	0.000204	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—uterine cancer	6.2e-05	0.000202	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—uterine cancer	6.2e-05	0.000201	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—uterine cancer	6.16e-05	0.0002	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—uterine cancer	6.15e-05	0.0002	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—uterine cancer	6.14e-05	0.000199	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—uterine cancer	6.1e-05	0.000198	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—uterine cancer	6.08e-05	0.000197	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—uterine cancer	6.05e-05	0.000197	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—uterine cancer	6.05e-05	0.000197	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—uterine cancer	6.05e-05	0.000197	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—uterine cancer	6.04e-05	0.000196	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—uterine cancer	5.98e-05	0.000194	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—uterine cancer	5.93e-05	0.000193	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—uterine cancer	5.89e-05	0.000191	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—uterine cancer	5.85e-05	0.00019	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—uterine cancer	5.81e-05	0.000189	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—uterine cancer	5.8e-05	0.000188	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—uterine cancer	5.8e-05	0.000188	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—uterine cancer	5.76e-05	0.000187	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—uterine cancer	5.74e-05	0.000186	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—uterine cancer	5.71e-05	0.000185	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—uterine cancer	5.7e-05	0.000185	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—uterine cancer	5.68e-05	0.000185	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—uterine cancer	5.68e-05	0.000184	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—uterine cancer	5.66e-05	0.000184	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—uterine cancer	5.61e-05	0.000182	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—uterine cancer	5.6e-05	0.000182	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—uterine cancer	5.6e-05	0.000182	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—uterine cancer	5.6e-05	0.000182	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—uterine cancer	5.53e-05	0.00018	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—uterine cancer	5.53e-05	0.00018	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—uterine cancer	5.42e-05	0.000176	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—uterine cancer	5.41e-05	0.000176	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—uterine cancer	5.37e-05	0.000174	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—uterine cancer	5.37e-05	0.000174	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—uterine cancer	5.33e-05	0.000173	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.28e-05	0.000172	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—uterine cancer	5.28e-05	0.000172	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—uterine cancer	5.25e-05	0.000171	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—uterine cancer	5.24e-05	0.00017	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—uterine cancer	5.21e-05	0.000169	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—uterine cancer	5.19e-05	0.000169	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—uterine cancer	5.17e-05	0.000168	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—uterine cancer	5.12e-05	0.000166	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—uterine cancer	5.04e-05	0.000164	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—uterine cancer	5.01e-05	0.000163	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—uterine cancer	5e-05	0.000162	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—uterine cancer	4.96e-05	0.000161	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—uterine cancer	4.96e-05	0.000161	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.89e-05	0.000159	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—uterine cancer	4.82e-05	0.000157	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—uterine cancer	4.78e-05	0.000155	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—uterine cancer	4.78e-05	0.000155	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—uterine cancer	4.66e-05	0.000152	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—uterine cancer	4.63e-05	0.00015	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—uterine cancer	4.61e-05	0.00015	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—uterine cancer	4.59e-05	0.000149	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—uterine cancer	4.59e-05	0.000149	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—uterine cancer	4.58e-05	0.000149	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—uterine cancer	4.42e-05	0.000144	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—uterine cancer	4.27e-05	0.000139	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—uterine cancer	4.26e-05	0.000139	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—uterine cancer	4.24e-05	0.000138	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—uterine cancer	4.16e-05	0.000135	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—uterine cancer	4.1e-05	0.000133	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—uterine cancer	3.97e-05	0.000129	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—uterine cancer	3.95e-05	0.000128	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—uterine cancer	3.85e-05	0.000125	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—uterine cancer	3.84e-05	0.000125	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—uterine cancer	3.8e-05	0.000123	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—uterine cancer	3.69e-05	0.00012	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—uterine cancer	3.67e-05	0.000119	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—uterine cancer	3.66e-05	0.000119	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—uterine cancer	3.65e-05	0.000119	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—uterine cancer	3.63e-05	0.000118	CcSEcCtD
Cyclophosphamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.57e-05	0.00201	CbGpPWpGaD
Cyclophosphamide—Dizziness—Doxorubicin—uterine cancer	3.55e-05	0.000115	CcSEcCtD
Cyclophosphamide—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	3.53e-05	0.00199	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	3.48e-05	0.00196	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.47e-05	0.00196	CbGpPWpGaD
Cyclophosphamide—Nausea—Epirubicin—uterine cancer	3.44e-05	0.000112	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—uterine cancer	3.41e-05	0.000111	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—uterine cancer	3.38e-05	0.00011	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—uterine cancer	3.38e-05	0.00011	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—uterine cancer	3.36e-05	0.000109	CcSEcCtD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	3.36e-05	0.0019	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—AKR1B1—uterine cancer	3.3e-05	0.00186	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—STAR—uterine cancer	3.3e-05	0.00186	CbGpPWpGaD
Cyclophosphamide—Nausea—Doxorubicin—uterine cancer	3.19e-05	0.000104	CcSEcCtD
Cyclophosphamide—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	3.15e-05	0.00178	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.12e-05	0.00176	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	3.12e-05	0.00176	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	3.11e-05	0.00175	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.08e-05	0.00174	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.08e-05	0.00174	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—SRD5A2—uterine cancer	3.03e-05	0.00171	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—NDUFB11—uterine cancer	3.03e-05	0.00171	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	2.9e-05	0.00164	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	2.87e-05	0.00162	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	2.86e-05	0.00161	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	2.83e-05	0.0016	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	2.83e-05	0.0016	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—NDUFB11—uterine cancer	2.78e-05	0.00157	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—SRD5A2—uterine cancer	2.78e-05	0.00157	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.75e-05	0.00155	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.75e-05	0.00155	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	2.74e-05	0.00154	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—CXCL8—uterine cancer	2.67e-05	0.0015	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	2.64e-05	0.00149	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—POLD1—uterine cancer	2.59e-05	0.00146	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.58e-05	0.00145	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	2.55e-05	0.00144	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.54e-05	0.00143	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	2.54e-05	0.00143	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.51e-05	0.00141	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.51e-05	0.00141	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	2.5e-05	0.00141	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—AKR1C1—uterine cancer	2.42e-05	0.00136	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.4e-05	0.00135	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.26e-05	0.00128	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NDUFB11—uterine cancer	2.24e-05	0.00126	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—SRD5A2—uterine cancer	2.24e-05	0.00126	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—AKR1B1—uterine cancer	2.19e-05	0.00124	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—STAR—uterine cancer	2.19e-05	0.00124	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NDUFB11—uterine cancer	2.19e-05	0.00124	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—SRD5A2—uterine cancer	2.19e-05	0.00124	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—VEGFA—uterine cancer	2.16e-05	0.00122	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—RRM2—uterine cancer	2.16e-05	0.00122	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—DCN—uterine cancer	2.09e-05	0.00118	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.02e-05	0.00114	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—AKR1B1—uterine cancer	2.01e-05	0.00113	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—STAR—uterine cancer	2.01e-05	0.00113	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP11A1—uterine cancer	1.97e-05	0.00111	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—SRD5A2—uterine cancer	1.9e-05	0.00107	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NDUFB11—uterine cancer	1.9e-05	0.00107	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.9e-05	0.00107	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	1.89e-05	0.00107	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.87e-05	0.00105	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—AKR1C3—uterine cancer	1.86e-05	0.00105	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.84e-05	0.00104	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.84e-05	0.00104	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.74e-05	0.000982	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—POLD1—uterine cancer	1.72e-05	0.00097	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SRD5A2—uterine cancer	1.69e-05	0.000955	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NDUFB11—uterine cancer	1.69e-05	0.000955	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SRD5A2—uterine cancer	1.65e-05	0.000933	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NDUFB11—uterine cancer	1.65e-05	0.000933	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.65e-05	0.000928	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—STAR—uterine cancer	1.62e-05	0.000914	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—AKR1B1—uterine cancer	1.62e-05	0.000914	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—AKR1C1—uterine cancer	1.61e-05	0.000907	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	1.6e-05	0.0009	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—AKR1B1—uterine cancer	1.58e-05	0.000893	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—STAR—uterine cancer	1.58e-05	0.000893	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—POLD1—uterine cancer	1.58e-05	0.000889	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NDUFB11—uterine cancer	1.56e-05	0.000879	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SRD5A2—uterine cancer	1.56e-05	0.000879	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.55e-05	0.000876	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SRD5A2—uterine cancer	1.54e-05	0.000871	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NDUFB11—uterine cancer	1.54e-05	0.000871	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.5e-05	0.000846	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—AKR1C1—uterine cancer	1.47e-05	0.000832	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—STK11—uterine cancer	1.45e-05	0.000818	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP19A1—uterine cancer	1.45e-05	0.000818	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—RRM2—uterine cancer	1.43e-05	0.000809	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.42e-05	0.000799	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—DCN—uterine cancer	1.39e-05	0.000785	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.39e-05	0.000782	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—AKR1B1—uterine cancer	1.37e-05	0.000774	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—STAR—uterine cancer	1.37e-05	0.000774	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.36e-05	0.000765	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—RRM2—uterine cancer	1.31e-05	0.000741	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP11A1—uterine cancer	1.31e-05	0.00074	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.28e-05	0.000725	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—DCN—uterine cancer	1.28e-05	0.00072	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—POLD1—uterine cancer	1.27e-05	0.000717	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—POLD1—uterine cancer	1.24e-05	0.000701	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—AKR1C3—uterine cancer	1.24e-05	0.000698	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—STAR—uterine cancer	1.22e-05	0.000691	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.22e-05	0.000691	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.21e-05	0.000685	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.21e-05	0.000683	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP11A1—uterine cancer	1.2e-05	0.000678	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—AKR1B1—uterine cancer	1.2e-05	0.000674	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—STAR—uterine cancer	1.2e-05	0.000674	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—AKR1C1—uterine cancer	1.19e-05	0.000671	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.18e-05	0.000667	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.16e-05	0.000656	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—AKR1C3—uterine cancer	1.13e-05	0.00064	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.13e-05	0.000636	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.13e-05	0.000635	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—STAR—uterine cancer	1.13e-05	0.000635	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—STAR—uterine cancer	1.12e-05	0.00063	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.12e-05	0.00063	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.1e-05	0.000623	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—MTHFR—uterine cancer	1.09e-05	0.000615	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—POLD1—uterine cancer	1.08e-05	0.000607	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.07e-05	0.000603	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—RRM2—uterine cancer	1.06e-05	0.000598	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—RRM2—uterine cancer	1.04e-05	0.000585	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—DCN—uterine cancer	1.03e-05	0.000581	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.02e-05	0.000575	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.02e-05	0.000575	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.01e-05	0.000568	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—DCN—uterine cancer	1.01e-05	0.000567	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP11A1—uterine cancer	9.7e-06	0.000547	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—STK11—uterine cancer	9.65e-06	0.000544	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP19A1—uterine cancer	9.65e-06	0.000544	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—POLD1—uterine cancer	9.61e-06	0.000542	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP11A1—uterine cancer	9.48e-06	0.000535	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—POLD1—uterine cancer	9.38e-06	0.000529	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—AKR1C3—uterine cancer	9.16e-06	0.000517	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	9.08e-06	0.000512	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—AKR1C1—uterine cancer	8.99e-06	0.000507	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—RRM2—uterine cancer	8.98e-06	0.000506	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—AKR1C3—uterine cancer	8.95e-06	0.000505	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—STK11—uterine cancer	8.84e-06	0.000499	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP19A1—uterine cancer	8.84e-06	0.000499	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—POLD1—uterine cancer	8.84e-06	0.000499	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—AKR1C1—uterine cancer	8.77e-06	0.000495	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—POLD1—uterine cancer	8.76e-06	0.000494	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—DCN—uterine cancer	8.71e-06	0.000491	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	8.34e-06	0.000471	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—AKR1C1—uterine cancer	8.27e-06	0.000466	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP11A1—uterine cancer	8.21e-06	0.000463	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—AKR1C1—uterine cancer	8.2e-06	0.000462	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	8.07e-06	0.000455	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—RRM2—uterine cancer	8.01e-06	0.000452	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—RRM2—uterine cancer	7.82e-06	0.000441	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—DCN—uterine cancer	7.78e-06	0.000439	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—AKR1C3—uterine cancer	7.75e-06	0.000437	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—DCN—uterine cancer	7.59e-06	0.000428	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—RRM2—uterine cancer	7.37e-06	0.000416	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—STAR—uterine cancer	7.36e-06	0.000415	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AKR1B1—uterine cancer	7.36e-06	0.000415	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP11A1—uterine cancer	7.33e-06	0.000413	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—RRM2—uterine cancer	7.31e-06	0.000412	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—MTHFR—uterine cancer	7.25e-06	0.000409	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—DCN—uterine cancer	7.15e-06	0.000403	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP11A1—uterine cancer	7.15e-06	0.000403	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—STK11—uterine cancer	7.13e-06	0.000402	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP19A1—uterine cancer	7.13e-06	0.000402	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—DCN—uterine cancer	7.09e-06	0.0004	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—STK11—uterine cancer	6.97e-06	0.000393	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP19A1—uterine cancer	6.97e-06	0.000393	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—AKR1C3—uterine cancer	6.92e-06	0.00039	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.82e-06	0.000384	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—AKR1C3—uterine cancer	6.75e-06	0.000381	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP11A1—uterine cancer	6.74e-06	0.00038	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP11A1—uterine cancer	6.68e-06	0.000377	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—MTHFR—uterine cancer	6.64e-06	0.000375	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—AKR1C3—uterine cancer	6.36e-06	0.000359	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—AKR1C3—uterine cancer	6.31e-06	0.000356	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTEN—uterine cancer	6.07e-06	0.000342	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP19A1—uterine cancer	6.04e-06	0.000341	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—STK11—uterine cancer	6.04e-06	0.000341	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—EP300—uterine cancer	5.79e-06	0.000326	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—POLD1—uterine cancer	5.78e-06	0.000326	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.67e-06	0.00032	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.41e-06	0.000305	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AKR1C1—uterine cancer	5.41e-06	0.000305	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—STK11—uterine cancer	5.39e-06	0.000304	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP19A1—uterine cancer	5.39e-06	0.000304	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—MTHFR—uterine cancer	5.36e-06	0.000302	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP19A1—uterine cancer	5.26e-06	0.000297	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—STK11—uterine cancer	5.26e-06	0.000297	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—MTHFR—uterine cancer	5.24e-06	0.000296	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.06e-06	0.000285	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP19A1—uterine cancer	4.96e-06	0.00028	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—STK11—uterine cancer	4.96e-06	0.00028	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.92e-06	0.000277	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—STK11—uterine cancer	4.92e-06	0.000277	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.83e-06	0.000272	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—RRM2—uterine cancer	4.82e-06	0.000272	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—DCN—uterine cancer	4.68e-06	0.000264	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.61e-06	0.00026	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—MTHFR—uterine cancer	4.54e-06	0.000256	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.41e-06	0.000249	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.4e-06	0.000248	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CA—uterine cancer	4.28e-06	0.000241	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.16e-06	0.000235	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—MTHFR—uterine cancer	4.05e-06	0.000229	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTEN—uterine cancer	4.03e-06	0.000227	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4e-06	0.000226	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—MTHFR—uterine cancer	3.95e-06	0.000223	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—EP300—uterine cancer	3.85e-06	0.000217	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—MTHFR—uterine cancer	3.73e-06	0.00021	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTEN—uterine cancer	3.7e-06	0.000208	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—MTHFR—uterine cancer	3.69e-06	0.000208	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.57e-06	0.000201	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—EP300—uterine cancer	3.53e-06	0.000199	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—AKT1—uterine cancer	3.5e-06	0.000197	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.26e-06	0.000184	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—STK11—uterine cancer	3.24e-06	0.000183	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.24e-06	0.000183	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTEN—uterine cancer	2.98e-06	0.000168	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTEN—uterine cancer	2.92e-06	0.000164	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CA—uterine cancer	2.84e-06	0.00016	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—EP300—uterine cancer	2.84e-06	0.00016	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—EP300—uterine cancer	2.78e-06	0.000157	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CA—uterine cancer	2.61e-06	0.000147	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTEN—uterine cancer	2.52e-06	0.000142	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—MTHFR—uterine cancer	2.44e-06	0.000137	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—EP300—uterine cancer	2.41e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—AKT1—uterine cancer	2.32e-06	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTEN—uterine cancer	2.25e-06	0.000127	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTEN—uterine cancer	2.2e-06	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—EP300—uterine cancer	2.15e-06	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—AKT1—uterine cancer	2.13e-06	0.00012	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CA—uterine cancer	2.1e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—EP300—uterine cancer	2.1e-06	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTEN—uterine cancer	2.07e-06	0.000117	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.06e-06	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTEN—uterine cancer	2.05e-06	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—EP300—uterine cancer	1.98e-06	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—EP300—uterine cancer	1.96e-06	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.78e-06	0.0001	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—AKT1—uterine cancer	1.72e-06	9.69e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—AKT1—uterine cancer	1.68e-06	9.48e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.59e-06	8.97e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CA—uterine cancer	1.55e-06	8.75e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.46e-06	8.25e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—AKT1—uterine cancer	1.46e-06	8.21e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.45e-06	8.18e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTEN—uterine cancer	1.36e-06	7.64e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—AKT1—uterine cancer	1.3e-06	7.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—EP300—uterine cancer	1.29e-06	7.29e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—AKT1—uterine cancer	1.27e-06	7.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—AKT1—uterine cancer	1.19e-06	6.74e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—AKT1—uterine cancer	1.18e-06	6.68e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CA—uterine cancer	9.56e-07	5.39e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AKT1—uterine cancer	7.81e-07	4.41e-05	CbGpPWpGaD
